Akebia Therapeutics reported total revenue of $69.6 million for Q4 2019, compared to $59.9 million for Q4 2018. The company's net loss for the quarter was $94.5 million, compared to $60.1 million for the same period in the previous year. The company's cash, cash equivalents and available-for-sale securities as of December 31, 2019 were $147.7 million.
Top-line data readouts of global Phase 3 program for vadadustat on track for Q2 of 2020 and mid-2020.
Company extends cash runway well into 2021.
Total revenue was $69.6 million for the fourth quarter of 2019 compared to $59.9 million for the fourth quarter of 2018.
Net loss was $94.5 million for the fourth quarter of 2019 compared to $60.1 million for the fourth quarter of 2018.
Akebia is focused on advancing its global Phase 3 program for vadadustat and anticipates top-line data readouts in Q2 2020 and mid-2020. The company expects to potentially access a Priority Review Voucher (PRV) for the vadadustat New Drug Application (NDA) to expedite FDA review.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance